ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
1-Year Return
26.77%
This Quarter Return
-5.04%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$497M
AUM Growth
+$130M
(+36%)
Cap. Flow
+$141M
Cap. Flow
% of AUM
28.38%
Top 10 Holdings %
Top 10 Hldgs %
61.21%
Holding
306
New
59
Increased
90
Reduced
44
Closed
53
Top Buys
| 1 |
Cytokinetics
CYTK
|
$29M |
| 2 |
Protagonist Therapeutics
PTGX
|
$28.4M |
| 3 |
BridgeBio Pharma
BBIO
|
$18.1M |
| 4 |
Roivant Sciences
ROIV
|
$14.4M |
| 5 |
Royalty Pharma
RPRX
|
$12.1M |
Top Sells
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$43.3M |
| 2 |
MACK
Merrimack Pharmaceuticals, Inc.
MACK
|
$13.3M |
| 3 |
Sarepta Therapeutics
SRPT
|
$4.21M |
| 4 |
EDR
Endeavor Group Holdings, Inc.
EDR
|
$3.91M |
| 5 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
$3.78M |
Sector Composition
| 1 | Healthcare | 85.86% |
| 2 | Financials | 1.87% |
| 3 | Industrials | 0.23% |
| 4 | Utilities | 0.18% |
| 5 | Materials | 0.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
RAPT Therapeutics
RAPT
$210M
| $22.9K | ﹤0.01% |
+938
| New | +$22.9K |
|
202
GH Research
GHRS
$876M
| $21.6K | ﹤0.01% |
1,850
-10,733
| -85% | -$125K |
|
203
Acadia Pharmaceuticals
ACAD
$4.31B
| $21.1K | ﹤0.01% |
1,300
+800
| +160% | +$13K |
|
204
Lexeo Therapeutics
LXEO
$275M
| $20.9K | ﹤0.01% |
+1,300
| New | +$20.9K |
|
205
Amplify Energy
AMPY
$160M
| $19.9K | ﹤0.01% |
2,928
-4,153
| -59% | -$28.2K |
|
206
Hims & Hers Health
HIMS
$10.8B
| $19K | ﹤0.01% |
+940
| New | +$19K |
|
|
PRTC
207
PureTech Health
PRTC
$383M
| $17.5K | ﹤0.01% |
+700
| New | +$17.5K |
|
|
TMTCR
208
DELISTED
TMT Acquisition Corp Rights
TMTCR
| $17K | ﹤0.01% |
49,900
| – | – |
|
209
Rallybio
RLYB
$25M
| $15K | ﹤0.01% |
11,200
-6,742
| -38% | -$9.03K |
|
|
GLSTR
210
DELISTED
Global Star Acquisition, Inc. Right
GLSTR
| $14.8K | ﹤0.01% |
118,400
| – | – |
|
211
Ovid Therapeutics
OVID
$91M
| $14.8K | ﹤0.01% |
19,190
+2,744
| +17% | +$2.11K |
|
212
Arcutis Biotherapeutics
ARQT
$1.97B
| $14.5K | ﹤0.01% |
1,555
-2,699
| -63% | -$25.1K |
|
213
Celldex Therapeutics
CLDX
$1.53B
| $11.2K | ﹤0.01% |
+303
| New | +$11.2K |
|
214
IDEAYA Biosciences
IDYA
$2.28B
| $10.5K | ﹤0.01% |
+300
| New | +$10.5K |
|
215
Zevra Therapeutics
ZVRA
$500M
| $9.8K | ﹤0.01% |
+2,000
| New | +$9.8K |
|
|
OKLO
216
Oklo
OKLO
$10.4B
| $8.47K | ﹤0.01% |
+1,000
| New | +$8.47K |
|
217
AstraZeneca
AZN
$254B
| $7.8K | ﹤0.01% |
100
-100
| -50% | -$7.8K |
|
218
Oak Woods Acquisition Corporation Right
OAKUR
| $7.5K | ﹤0.01% |
30,000
| – | – |
|
|
ADXN
219
Addex Therapeutics
ADXN
| $7.4K | ﹤0.01% |
900
+510
| +131% | +$4.19K |
|
220
Erasca
ERAS
$431M
| $7.32K | ﹤0.01% |
+3,100
| New | +$7.32K |
|
|
BLUE
221
DELISTED
bluebird bio
BLUE
| $5.91K | ﹤0.01% |
300
+50
| +20% | +$984 |
|
222
enGene Holdings
ENGN
$255M
| $5.66K | ﹤0.01% |
+600
| New | +$5.66K |
|
223
Arcellx
ACLX
$3.95B
| $5.52K | ﹤0.01% |
+100
| New | +$5.52K |
|
224
Tyra Biosciences
TYRA
$670M
| $4.8K | ﹤0.01% |
300
-28,000
| -99% | -$448K |
|
225
Masimo
MASI
$7.87B
| $4.79K | ﹤0.01% |
38
| – | – |
|